The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.

Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.

Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.

In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller offers a recap from the recent TCT 2022 meeting and talks about Butterfly Network’s expansion into Africa while Marion Webb highlights her interview with Aidoc’s CEO Elad Walach discussing plans for the AI-based software company.